 |
18 Diseases |  |
2 Trials |
|
2 Trials |  |
132 News |  |
| «123» |
- || uprifosbuvir (IDX21437) / Merck (MSD), Ruzasvir (MK-8408) / Merck (MSD), grazoprevir (MK-5172) / Merck (MSD)
Clinical, Journal: Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection. (Pubmed Central) - Jul 25, 2020
P2
One participant experienced on-treatment alanine aminotransferase/aspartate aminotransferase elevations that resolved without intervention. Data from the present study indicate that the combination of RZR 60 mg plus UPR 450 mg once daily for 12 weeks was well-tolerated overall but was effective only for certain genotypes.
- | grazoprevir (MK-5172) / Merck (MSD)
Trial completion date, Trial primary completion date: Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) (clinicaltrials.gov) - Apr 22, 2020
P=N/A, N=3250, Enrolling by invitation, Sponsor: Merck Sharp & Dohme Corp.
Data from the present study indicate that the combination of RZR 60 mg plus UPR 450 mg once daily for 12 weeks was well-tolerated overall but was effective only for certain genotypes. Trial completion date: Jul 2023 --> May 2021 | Trial primary completion date: Jul 2023 --> May 2021
- | grazoprevir (MK-5172) / Merck (MSD)
Journal: Hemoprotein-catalyzed cyclopropanation en route to the chiral cyclopropanol fragment of grazoprevir. (Pubmed Central) - Feb 7, 2020
Here we describe hemoprotein cyclopropanation catalysts derived from thermophilic bacterial globins that react with diazoacetone and an unactivated olefin substrate to furnish a cyclopropyl ketone, a previously unreported reaction for enzyme catalysts. We further demonstrate that the resulting cyclopropyl ketone can be converted to a key cyclopropanol intermediate that occurs en route to the anti-hepatitis C drug grazoprevir.
- | grazoprevir (MK-5172) / Merck (MSD)
Observational data, Journal: Hepatitis C Virus among Female Sex Workers: A Cross-Sectional Study Conducted along Rivers and Highways in the Amazon Region. (Pubmed Central) - Nov 22, 2019
We further demonstrate that the resulting cyclopropyl ketone can be converted to a key cyclopropanol intermediate that occurs en route to the anti-hepatitis C drug grazoprevir. HCV infection among FSWs is highly prevalent and dominated by genotype I. Urgent preventive and treatment measures are required to reduce HCV infection in FSWs and the general population.
- | Ruzasvir (MK-8408) / Merck (MSD), grazoprevir (MK-5172) / Merck (MSD)
Preclinical, Journal: In Vitro Antiviral Profile of Ruzasvir: A Potent and Pan-genotype Inhibitor of HCV NS5A. (Pubmed Central) - Oct 10, 2019
The interaction of ruzasvir with NS3/4A protease inhibitor (grazoprevir) and NS5B polymerase (uprifosbuvir) pro-drug was additive to synergistic with no evidence of antagonism or cytotoxicity. The antiviral profile of ruzasvir supported its further evaluation in human trials in combination with grazoprevir and uprifosbuvir.
- | Journal: Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat? (Pubmed Central) - Sep 26, 2019
The antiviral profile of ruzasvir supported its further evaluation in human trials in combination with grazoprevir and uprifosbuvir. Data to determine the best treatment point along the pregnancy-pediatric continuum are limited; however, given the lack of human data for use of DAAs during pregnancy, low rate of VT, high rate of spontaneous pediatric clearance, and recent approval of DAAs for pediatric patients, treatment of chronically infected children seems to be the optimal strategy currently.
- | grazoprevir (MK-5172) / Merck (MSD), paritaprevir/ritonavir (ABT-450/r) / AbbVie
Clinical, Journal: Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease. (Pubmed Central) - Sep 20, 2019
For such inhibitors, the Y56H substitution disrupts favorable stacking interactions with the neighboring catalytic His57. This indirect mechanism of resistance threatens to cause multi-PI failure as all HCV PIs in clinical development rely on interactions with the catalytic triad.
- | grazoprevir (MK-5172) / Merck (MSD), elbasvir (MK-8742) / Merck (MSD)
Journal: Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in HCV GT2. (Pubmed Central) - Sep 19, 2019
Ruzasvir, a potent, pan-genotype NS5A inhibitor successfully inhibited replicons bearing GT2 resistance-associated substitutions (RASs) at positions 28 and 31. The studies demonstrate crosstalk between amino acids at positions 28 and 31 in NS5A modulate inhibitor potency and may impact treatment outcomes in some HCV GT2-infected patients.
- | Journal: Unexpected Replication Boost by Simeprevir for Simeprevir-resistant Variants in Genotype 1a Hepatitis C Virus. (Pubmed Central) - Sep 4, 2019
The boosted replication of Q80K+R155K by simeprevir could be related to treatment failure in simeprevir-containing antiviral treatments in gt 1a HCV-infected patients with the NS3-Q80K polymorphism. This result provides a new insight into how resistance-associated variants can cause treatment failure.
- | Review, Journal: HCV therapy: no one to let behind. (Pubmed Central) - Sep 4, 2019
New triple regimens have solved the issue of retreatment of the few patients who present failure to DAAs therapy. In the present review we describe the current HCV landscape that allows to cure nearly all HCV infected patients.
- | grazoprevir (MK-5172) / Merck (MSD), Sovaldi (sofosbuvir) / Gilead, elbasvir (MK-8742) / Merck (MSD)
Clinical, Journal: Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. (Pubmed Central) - Aug 9, 2019
P4
Recipients of kidneys from donors with genotype 1 infection continued receiving GZR-EBR for 12 weeks after transplantation; those receiving organs from donors with genotype 2 or 3 infection had sofosbuvir, 400 mg, added to GZR-EBR for 12 weeks of triple therapy...If confirmed in larger studies, this strategy should markedly expand organ options and reduce mortality for kidney transplant candidates without HCV infection. Merck Sharp & Dohme Corp.
- | uprifosbuvir (IDX21437) / Merck (MSD), Ruzasvir (MK-8408) / Merck (MSD), grazoprevir (MK-5172) / Merck (MSD)
Clinical, P2 data, Journal: Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. (Pubmed Central) - Jul 25, 2018
P2
Merck Sharp & Dohme Corp. The combined regimen of grazoprevir (100 mg/day), ruzasvir (60 mg/day), and uprifosbuvir (450 mg/day) has the potential to provide a simplified treatment for HCV that is effective and well tolerated in most individuals infected with HCV, as well as a shorter duration of treatment in many individuals.
- | grazoprevir (MK-5172) / Merck (MSD)
PK/PD data, Journal: The Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor. (Pubmed Central) - Jul 22, 2018
No dose adjustment is required for GZR in people with HCV with mild HI. GZR is contraindicated in those with moderate or severe HI (Child-Pugh B or C), as they may have significantly increased GZR exposures that may lead to increased risk of transaminase elevations.
- || grazoprevir (MK-5172) / Merck (MSD)
Trial primary completion date: Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) (clinicaltrials.gov) - Sep 27, 2017
P=N/A, N=3250, Enrolling by invitation, Sponsor: Merck Sharp & Dohme Corp.
GZR is contraindicated in those with moderate or severe HI (Child-Pugh B or C), as they may have significantly increased GZR exposures that may lead to increased risk of transaminase elevations. Trial primary completion date: May 2022 --> Jul 2023
- || grazoprevir (MK-5172) / Merck (MSD)
Trial primary completion date: Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) (clinicaltrials.gov) - Jun 22, 2017
P=N/A, N=3250, Enrolling by invitation, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: May 2022 --> Jul 2023 Trial primary completion date: Aug 2021 --> May 2022
- || Trial primary completion date: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) (clinicaltrials.gov) - Jun 2, 2017
P2, N=413, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Aug 2021 --> May 2022 Trial primary completion date: Feb 2017 --> Sep 2016
- |||| Trial completion: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) (clinicaltrials.gov) - May 8, 2017
P2, N=413, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Feb 2017 --> Sep 2016 Active, not recruiting --> Completed
- || grazoprevir (MK-5172) / Merck (MSD), ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial primary completion date: Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Na (clinicaltrials.gov) - Mar 30, 2017
P2, N=368, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Trial primary completion date: Mar 2015 --> Jan 2013
- | grazoprevir (MK-5172) / Merck (MSD)
Phase classification: Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) (clinicaltrials.gov) - Feb 11, 2017
P=N/A, N=3250, Enrolling by invitation, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Mar 2015 --> Jan 2013 Phase classification: P3 --> P=N/A
- |||| Trial completion: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011) (clinicaltrials.gov) - Dec 19, 2016
P2, N=443, Completed, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P3 --> P=N/A Active, not recruiting --> Completed
- | uprifosbuvir (IDX21437) / Merck (MSD), grazoprevir (MK-5172) / Merck (MSD)
Trial completion, Enrollment change: Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030) (clinicaltrials.gov) - Aug 30, 2016
P1, N=16, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=24 --> 16
- uprifosbuvir (IDX21437) / Merck (MSD), grazoprevir (MK-5172) / Merck (MSD)
Enrollment closed: Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030) (clinicaltrials.gov) - Aug 3, 2016
P1, N=24, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | N=24 --> 16 Recruiting --> Active, not recruiting
- |||| Enrollment open: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) (clinicaltrials.gov) - Jun 29, 2016
P2, N=500, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- ||| Enrollment closed: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) (clinicaltrials.gov) - Jun 20, 2016
P2, N=500, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- || grazoprevir (MK-5172) / Merck (MSD)
Phase classification: Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) (clinicaltrials.gov) - Jun 18, 2016
P3, N=3250, Enrolling by invitation, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Phase classification: P2 --> P3
- || Trial primary completion date: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) (clinicaltrials.gov) - Mar 25, 2016
P2, N=500, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P2 --> P3 Trial primary completion date: Sep 2016 --> Jan 2017
- ||| Enrollment closed: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011) (clinicaltrials.gov) - Mar 18, 2016
P2, N=465, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Sep 2016 --> Jan 2017 Recruiting --> Active, not recruiting
- || grazoprevir (MK-5172) / Merck (MSD)
Phase classification, Trial primary completion date: Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) (clinicaltrials.gov) - Mar 16, 2016
P2, N=3250, Enrolling by invitation, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Phase classification: P=N/A --> P2 | Trial primary completion date: Sep 2020 --> Sep 2021
- || grazoprevir (MK-5172) / Merck (MSD), ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial primary completion date: Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Na (clinicaltrials.gov) - Mar 2, 2016
P2, N=368, Completed, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P=N/A --> P2 | Trial primary completion date: Sep 2020 --> Sep 2021 Trial primary completion date: Jun 2012 --> Mar 2015
- uprifosbuvir (IDX21437) / Merck (MSD), grazoprevir (MK-5172) / Merck (MSD)
Enrollment open: Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030) (clinicaltrials.gov) - Feb 20, 2016
P1, N=24, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jun 2012 --> Mar 2015 Not yet recruiting --> Recruiting
- | uprifosbuvir (IDX21437) / Merck (MSD), grazoprevir (MK-5172) / Merck (MSD)
New P1 trial: Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030) (clinicaltrials.gov) - Jan 22, 2016
P1, N=24, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- || Trial primary completion date: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011) (clinicaltrials.gov) - Oct 27, 2015
P2, N=465, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Jul 2016
- ||| Enrollment change, Trial primary completion date: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) (clinicaltrials.gov) - Oct 23, 2015
P2, N=460, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2015 --> Jul 2016 N=220 --> 460 | Trial primary completion date: Dec 2015 --> Jul 2016
- || grazoprevir (MK-5172) / Merck (MSD)
Trial primary completion date: Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) (clinicaltrials.gov) - Jun 26, 2015
P=N/A, N=3250, Enrolling by invitation, Sponsor: Merck Sharp & Dohme Corp.
N=220 --> 460 | Trial primary completion date: Dec 2015 --> Jul 2016 Trial primary completion date: Sep 2018 --> Sep 2020
- |||| grazoprevir (MK-5172) / Merck (MSD), ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion: Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Na (clinicaltrials.gov) - Mar 17, 2015
P2, N=368, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Sep 2018 --> Sep 2020 Active, not recruiting --> Completed
- |||| Enrollment open, Trial primary completion date: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011) (clinicaltrials.gov) - Feb 10, 2015
P2, N=480, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> Dec 2015
- |||| Enrollment open: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) (clinicaltrials.gov) - Feb 9, 2015
P2, N=220, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> Dec 2015 Not yet recruiting --> Recruiting
- ||||| New P2 trial: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) (clinicaltrials.gov) - Jan 7, 2015
P2, N=220, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||||| New P2 trial: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011) (clinicaltrials.gov) - Jan 7, 2015
P2, N=480, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- grazoprevir (MK-5172) / Merck (MSD)
Trial completion, Trial primary completion date: A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010) (clinicaltrials.gov) - Oct 27, 2014
P1, N=4, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Oct 2014 --> Jul 2014
- | grazoprevir (MK-5172) / Merck (MSD)
Trial completion: Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013) (clinicaltrials.gov) - Oct 2, 2014
P1, N=48, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | Trial primary completion date: Oct 2014 --> Jul 2014 Active, not recruiting --> Completed
- grazoprevir (MK-5172) / Merck (MSD)
Enrollment closed: Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013) (clinicaltrials.gov) - Sep 8, 2014
P1, N=48, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || grazoprevir (MK-5172) / Merck (MSD), ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion date: A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Na (clinicaltrials.gov) - Apr 30, 2014
P2, N=87, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Trial completion date: May 2014 --> Jan 2014
- |||| grazoprevir (MK-5172) / Merck (MSD), ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion: A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Na (clinicaltrials.gov) - Apr 30, 2014
P2, N=87, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: May 2014 --> Jan 2014 Active, not recruiting --> Completed
- | grazoprevir (MK-5172) / Merck (MSD)
Trial completion, Combination therapy: A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039) (clinicaltrials.gov) - Mar 30, 2014
P2, N=26, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- grazoprevir (MK-5172) / Merck (MSD)
Enrollment open: A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010) (clinicaltrials.gov) - Oct 7, 2013
P1, N=8, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| grazoprevir (MK-5172) / Merck (MSD), ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Enrollment closed: Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Na (clinicaltrials.gov) - Jul 7, 2013
P2, N=390, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- grazoprevir (MK-5172) / Merck (MSD)
Enrollment change: A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010) (clinicaltrials.gov) - Jun 13, 2013
P1, N=8, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting N=16 --> 8
- grazoprevir (MK-5172) / Merck (MSD), ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Enrollment closed: A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Na (clinicaltrials.gov) - May 7, 2013
P2, N=87, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=16 --> 8 Recruiting --> Active, not recruiting
- ||| grazoprevir (MK-5172) / Merck (MSD)
Enrollment open: Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) (clinicaltrials.gov) - Dec 17, 2012
P=N/A, N=3250, Enrolling by invitation, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Not yet recruiting --> Enrolling by invitation